Abstract
A series of novel 3-O-arylalkylbenzamide derivatives as FtsZ inhibitors was designed, synthesized and evaluated for their cell division inhibitory activity against B. subtilis and S. aureus, and in vitro antibacterial activity against various phenotypes of Gram-positive bacteria. This series showed significantly improved on-target activity and in vitro antibacterial activity compared with 3-MBA. Among them, 3-O-alkylbenzamids 4–8 and 3-O-bromoalkylbenzamides 9 and 10 showed significantly improved activity against three phenotypes of S. aureus ATCC25923, S. aureusATCC29213 (MRSA) and S. aureus PR. Preliminary structure-activity relationships indicated that the extension of 3-O-alkyl side chain resulted in a substantial improvement in the antibacterial activity, and the small group like methyl or ethyl group at the position 1–3 of the 3-O-alkyl side chain did not affect the antibacterial activity while the large group such as benzene or heterocycle at the position 4 or 5 of the 3-O-alkyl side chain could lead to poor antibacterial activity.
Keywords: Antibacterial evaluation, 3-O-Arylalkyl groups, Benzamide derivatives, FtsZ inhibitors, Resistant bacteria, Synthesis
Letters in Drug Design & Discovery
Title:The Synthesis and Antibacterial Activity of Novel 3-O-arylalkylbenzamide Derivatives as FtsZ Inhibitors
Volume: 10 Issue: 4
Author(s): Siti Ma, Rongmei Wang, Yuanze Wang, Jichao Cao and Shutao Ma
Affiliation:
Keywords: Antibacterial evaluation, 3-O-Arylalkyl groups, Benzamide derivatives, FtsZ inhibitors, Resistant bacteria, Synthesis
Abstract: A series of novel 3-O-arylalkylbenzamide derivatives as FtsZ inhibitors was designed, synthesized and evaluated for their cell division inhibitory activity against B. subtilis and S. aureus, and in vitro antibacterial activity against various phenotypes of Gram-positive bacteria. This series showed significantly improved on-target activity and in vitro antibacterial activity compared with 3-MBA. Among them, 3-O-alkylbenzamids 4–8 and 3-O-bromoalkylbenzamides 9 and 10 showed significantly improved activity against three phenotypes of S. aureus ATCC25923, S. aureusATCC29213 (MRSA) and S. aureus PR. Preliminary structure-activity relationships indicated that the extension of 3-O-alkyl side chain resulted in a substantial improvement in the antibacterial activity, and the small group like methyl or ethyl group at the position 1–3 of the 3-O-alkyl side chain did not affect the antibacterial activity while the large group such as benzene or heterocycle at the position 4 or 5 of the 3-O-alkyl side chain could lead to poor antibacterial activity.
Export Options
About this article
Cite this article as:
Ma Siti, Wang Rongmei, Wang Yuanze, Cao Jichao and Ma Shutao, The Synthesis and Antibacterial Activity of Novel 3-O-arylalkylbenzamide Derivatives as FtsZ Inhibitors, Letters in Drug Design & Discovery 2013; 10 (4) . https://dx.doi.org/10.2174/1570180811310040005
DOI https://dx.doi.org/10.2174/1570180811310040005 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents
Current Pharmaceutical Design Drug-Induced QTc Prolongation: What We Know and Where We Are Going
Current Drug Safety Synthesis Strategies and Medicinal Value of Pyrrole and its Fused Heterocyclic Compounds
Medicinal Chemistry Repurposing Thalidomide, its Analogue and Apremilast for Possible Antiviral in Situation of Severe COVID Cytokine Syndrome
Infectious Disorders - Drug Targets Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Modular Synthesis of New Bicyclic Carbene Precursors
Letters in Organic Chemistry Quinoxalines Potential to Target Pathologies
Current Medicinal Chemistry Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target
Current Medicinal Chemistry Genetic Susceptibility to Ankylosing Spondylitis
Current Molecular Medicine Synthesis and Preliminary Anti-HIV Activities of Andrographolide Derivatives
Medicinal Chemistry Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Prevention and Management of Ovarian Hyperstimulation Syndrome
Current Women`s Health Reviews Meet Our Editorial Board Member
Current Drug Targets Acoustic Radiation Force Impulse (ARFI) Imaging: A Review
Current Medical Imaging The Structures and Bioactivities of Fatty Acid Synthase Inhibitors
Current Medicinal Chemistry A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Carbon Monoxide - A Toxic Gas on the Edge to Clinical Application (Guest Editor: Rene Schmidt)]
Current Pharmaceutical Biotechnology